NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by NextCure, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 2 filings
- 1 insider, $1.71M in total
- Open-market sells
- 1 filing
- 1 insider, $184.8K in total
- Insiders trading
- 2
- Net value
- +$1.53M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for NextCure, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ren Jinsheng | Other: Former 10% Owner | 308,636Indirect | Aug 12, 2026 | 1 |
| Simcere Zaiming, Inc. | Other: Former 10% Owner | 308,636Indirect | Aug 12, 2026 | 1 |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | Other: Former 10% Owner | 308,636Indirect | Aug 12, 2026 | 1 |
| Simcere Pharmaceutical Group Ltd | Other: Former 10% Owner | 308,636Indirect | Aug 12, 2026 | 1 |
| Simcere Zaiming Pharmaceutical Co., Ltd. | Other: Former 10% Owner | 308,636Indirect | Aug 12, 2026 | 1 |
| Tang Renhong | Other: Former 10% Owner | 308,636Indirect | Aug 12, 2026 | 1 |
| Schneeberger Daniel | 10% Owner | 722,419Indirect | Aug 3, 2026 | 2 |
| ADAR1 Capital Management, LLC | 10% Owner | 722,419Indirect | Aug 3, 2026 | 2 |
| Kabakoff David S | Director | – | Jun 22, 2026 | 1 |
| Jones Elaine V | Director | – | Jun 22, 2026 | 1 |
| Webster Stephen W | Director | – | Jun 22, 2026 | 1 |
| Houston John G | Director | – | Jun 22, 2026 | 1 |
| Feigal Ellen | Director | – | Jun 22, 2026 | 1 |
| Borgman Anne Elizabeth | Director | – | Jun 22, 2026 | 1 |
| Richman Michael | President & CEO | – | Feb 3, 2026 | 1 |
| Cobourn Steven P. | Chief Financial Officer | – | Feb 3, 2026 | 1 |
| Mayer Timothy | Chief Operating Officer | – | Feb 3, 2026 | 1 |
| Kundu Sourav | Sr VP, Dev. & Mfg. | – | Feb 3, 2026 | 1 |
| Shaw Kevin G. | Sr VP, General Counsel | – | Feb 3, 2026 | 1 |
| Guha Udayan | Chief Medical Officer | – | Feb 3, 2026 | 1 |
| Langermann Sol | Chief Scientific Officer | – | Feb 3, 2025 | 0 |
| Myint Han | Chief Medical Officer | – | Apr 2, 2024 | 0 |
| Khuong Chau Quang | Director | – | Jun 23, 2023 | 0 |
| Nicholson Garry A | Director | – | Jun 23, 2023 | 0 |
| Liu Linda | SVP, Research | – | Feb 2, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 (view filing)11:35 AM ET | Aug 10 | 2 days | Ren Jinsheng and 5 othersOther: Former 10% Owner | SSale | −30.0K | $6.16 | −$184.8K | −8.9%308.6K after | |
| Aug 3, 2026 (view filing)5:53 PM ET | Jul 30-31 | 4 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +329.2K | $4.93 | +$1.62M | +83.7%722.4K after | 9 lots |
| Jul 29, 2026 (view filing)6:18 PM ET | Jul 27-29 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +17.6K | $4.98 | +$87.7K | +4.7%393.3K after | 4 lots |